MARKET

TLSI

TLSI

TriSalus Life Sciences Inc.
NASDAQ
3.340
+0.130
+4.05%
After Hours: 3.350 +0.01 +0.30% 19:06 06/09 EDT
OPEN
3.200
PREV CLOSE
3.210
HIGH
3.400
LOW
3.150
VOLUME
171.04K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
2.200
MARKET CAP
205.13M
P/E (TTM)
-2.3685
1D
5D
1M
3M
1Y
5Y
1D
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
PR Newswire · 1d ago
Weekly Report: what happened at TLSI last week (0601-0605)?
Weekly Report · 1d ago
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm
Barchart · 6d ago
Weekly Report: what happened at TLSI last week (0525-0529)?
Weekly Report · 06/01 09:37
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 05/29 14:00
Weekly Report: what happened at TLSI last week (0518-0522)?
Weekly Report · 05/25 09:39
Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 05/20 11:00
TLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities Fraud
Barchart · 05/19 15:00
More
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

Webull offers TriSalus Life Sciences Inc stock information, including NASDAQ: TLSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSI stock methods without spending real money on the virtual paper trading platform.